Table 1.
Summary of demographic and baseline characteristics, stratified by tenofovir exposure status at end of study.
| Risk factor | TDF exposure (n = 14 687) | No TDF exposure (n = 6903) |
|---|---|---|
| Age (years)a | 47 (40, 53) | 48 (42, 54) |
| Black | 52% | 56% |
| Glucose (mg/dl) | 95 (87, 106) | 96 (87, 109) |
| Diabetic | 5.4% | 7.0% |
| SBP (mmHg) | 127 (116, 138) | 128 (115, 140) |
| DBP (mmHg) | 77 (70, 85) | 77 (70, 85) |
| Hypertension | 27% | 28% |
| ACE-I or ARB use | 5.8% | 7.4% |
| Statin use | 3.8% | 3.4% |
| Proteinuria | 23% | 23% |
| HDL cholesterol (mg/dl) | 38 (30, 47) | 39 (31, 49) |
| LDL cholesterol (mg/dl) | 100 (78, 125) | 101 (76, 129) |
| Triglycerides (mg/dl) | 138 (94, 216) | 144 (98, 223) |
| CVD | 3.9% | 4.9% |
| Current smoking | 21% | 17% |
| BMI (kg/m2) | 25 (22, 28) | 24 (22, 27) |
| Illicit drug use | 26% | 28% |
| HIV viral load (/1000) | 14 (0, 92) | 10 (0, 93) |
| CD4+ cell count (cells/μl) | 314 (160, 492) | 310 (143, 526) |
| Hepatitis C virus infection | 23% | 28% |
| Hepatitic B virus infection | 7.5% | 7.0% |
ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CVD, cardiovascular disease; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; TDF, tenofovir disoproxil fumarate.
a
Continuous variables reported as median (IQR). Proteinuria defined by urinalysis protein 30 mg/dl or greater.